iQure Pharma Inc.

📢 𝗦𝘁𝗮𝘆 𝗜𝗻𝗳𝗼𝗿𝗺𝗲𝗱: 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗡𝗲𝘄𝘀 𝗥𝗼𝘂𝗻𝗱𝘂𝗽 📢 21st Feb 2025 - Discover the latest advancements in the pharmaceutical industry with our daily news update. Our roundup includes crucial FDA designations, innovative drug developments, and impactful clinical trial outcomes analysis. Stay ahead and grow faster. #pharmanews #biopharma #fdaapprovals #clinicaltrials #drugdevelopment #pharmadaily #thelansis #TelomereBiologyDisorders #TBDs #DravetSyndrome #DS #DuchenneMuscularDystrophy #DMD #DiffuseGastricCancer #DegenerativeDiscDisease #DDD #DiabeticFootUlcer #DFU

iQure Pharma Inc. is a biotech company focused on developing new treatments for neurodegenerative diseases. Last month, they announced their latest round of funding: $4 million to progress with a Phase 1 clinical trial for its lead asset iQ-007, a novel therapeutic candidate to treat epilepsy and other neurodegenerative conditions. 👏👏 iQure’s mission is to provide better options for patients struggling with these challenging conditions. Our mission is to continue to help iQure unlock the power of equity as they grow. Congrats, Pawel and the whole iQure team on your latest funding round! 🥳 #BioTech #StartupFundraising #EquityManagement

I just registered for BIO-Europe Spring on March 17–19, 2025. Join me at the premier springtime partnering event >> https://lnkd.in/eegrBD5y #BIOEuropeSpring Informa Connect

I'll be attending BIO-Europe Spring on March 17–19, 2025. Join me at the premier springtime partnering event >> https://lnkd.in/eH-sThMf #BIOEuropeSpring Informa Connect

✨Portfolio news!   The newest member of our portfolio, iQure Pharma Inc., has received Orphan Drug Designation from the FDA for its drug iQ-007, designed for the treatment of Dravet syndrome, a rare and severe form of epilepsy. Orphan drug designation is a special status granted by regulatory authorities to encourage the development of treatments for rare diseases affecting a small number of patients, offering incentives like market exclusivity, tax credits, and fee waivers.   🤝 We are committed to supporting iQure Pharma on developing new therapeutics for neurodegenerative diseases. #BiotechInnovation #OrphanDrugs #RareDiseaseResearch #DrugDevelopment #BiotechStartups #DravetSyndrome #LifeSciences

FDA signals significant support for iQ-007 with Orphan Drug Designation (ODD) for Dravet's Syndrome

Everything in place for the next exciting phase in the development of iQ-007 in neurodegenerative diseases.

Major funding milestone for iQure Pharma greenlights iQ-007 for Phase 1 Clinical Trial! Congratulations to the entire team!

I'm looking forward to attending Biotech Showcase 2025! Join me in San Francisco, January 13–15, 2025 https://lnkd.in/euTidncx #BiotechShowcase Informa Connect

Our iQure CSO honored by Polish President.